Frailty in Hematologic Malignancy

Thuy T Koll, Ashley E. Rosko

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of Review: Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. Recent Findings: Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in improved prognostication to decrease morbidity and mortality. Frailty is not synonymous with individual performance status and is dynamic. Summary: Establishing the patient goals, values, and preferences is central to the consideration of malignant hematology decision process. Careful considerations of available data on the patient’s prognosis based on estimated life expectancy, geriatric assessment data, and age-specific cancer mortality, with and without treatment, can reconcile the risks and benefits. Assessments of frailty can aid the clinical feasibility and burden of the treatment to the patient and family in the context of each patient’s unique needs.

Original languageEnglish (US)
Pages (from-to)143-154
Number of pages12
JournalCurrent Hematologic Malignancy Reports
Volume13
Issue number3
DOIs
StatePublished - Jun 1 2018

Fingerprint

Hematologic Neoplasms
Geriatric Assessment
Mortality
Hematology
Life Expectancy
Geriatrics
Therapeutics
Quality of Life
Demography
Morbidity
Drug Therapy
Neoplasms

Keywords

  • Frailty
  • Geriatric assessment
  • Hematologic malignancy
  • Older adults

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Frailty in Hematologic Malignancy. / Koll, Thuy T; Rosko, Ashley E.

In: Current Hematologic Malignancy Reports, Vol. 13, No. 3, 01.06.2018, p. 143-154.

Research output: Contribution to journalReview article

Koll, Thuy T ; Rosko, Ashley E. / Frailty in Hematologic Malignancy. In: Current Hematologic Malignancy Reports. 2018 ; Vol. 13, No. 3. pp. 143-154.
@article{e8f030c3bcb0417084700b9b8676a960,
title = "Frailty in Hematologic Malignancy",
abstract = "Purpose of Review: Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. Recent Findings: Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in improved prognostication to decrease morbidity and mortality. Frailty is not synonymous with individual performance status and is dynamic. Summary: Establishing the patient goals, values, and preferences is central to the consideration of malignant hematology decision process. Careful considerations of available data on the patient’s prognosis based on estimated life expectancy, geriatric assessment data, and age-specific cancer mortality, with and without treatment, can reconcile the risks and benefits. Assessments of frailty can aid the clinical feasibility and burden of the treatment to the patient and family in the context of each patient’s unique needs.",
keywords = "Frailty, Geriatric assessment, Hematologic malignancy, Older adults",
author = "Koll, {Thuy T} and Rosko, {Ashley E.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s11899-018-0454-x",
language = "English (US)",
volume = "13",
pages = "143--154",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Frailty in Hematologic Malignancy

AU - Koll, Thuy T

AU - Rosko, Ashley E.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose of Review: Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. Recent Findings: Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in improved prognostication to decrease morbidity and mortality. Frailty is not synonymous with individual performance status and is dynamic. Summary: Establishing the patient goals, values, and preferences is central to the consideration of malignant hematology decision process. Careful considerations of available data on the patient’s prognosis based on estimated life expectancy, geriatric assessment data, and age-specific cancer mortality, with and without treatment, can reconcile the risks and benefits. Assessments of frailty can aid the clinical feasibility and burden of the treatment to the patient and family in the context of each patient’s unique needs.

AB - Purpose of Review: Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. Recent Findings: Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in improved prognostication to decrease morbidity and mortality. Frailty is not synonymous with individual performance status and is dynamic. Summary: Establishing the patient goals, values, and preferences is central to the consideration of malignant hematology decision process. Careful considerations of available data on the patient’s prognosis based on estimated life expectancy, geriatric assessment data, and age-specific cancer mortality, with and without treatment, can reconcile the risks and benefits. Assessments of frailty can aid the clinical feasibility and burden of the treatment to the patient and family in the context of each patient’s unique needs.

KW - Frailty

KW - Geriatric assessment

KW - Hematologic malignancy

KW - Older adults

UR - http://www.scopus.com/inward/record.url?scp=85046490145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046490145&partnerID=8YFLogxK

U2 - 10.1007/s11899-018-0454-x

DO - 10.1007/s11899-018-0454-x

M3 - Review article

C2 - 29730710

AN - SCOPUS:85046490145

VL - 13

SP - 143

EP - 154

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 3

ER -